Pemigatinib

佩米替尼

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NamePemigatinib
Drug Alias Name派美替尼培美替尼培米替尼Pemazyre伯坦 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonistsFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3
Therapy Area/IndicationsSolid tumoursTranslocation, GeneticMyeloproliferative Disorders +[29] 
Global Approved IndicationsBile Duct NeoplasmsBiliary Tract NeoplasmsCholangiocarcinoma
Approved Indications in ChinaBiliary Tract Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2020/04/17
Country/TerritoryBelgiumCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityKnight TherapeuticsDana-Farber Cancer Institute +[10] 
Inactive CompaniesHonorhealth Research InstituteXcelience LlcIncyte Biosciences International Sàrl +[4] 
Active IndicationsTranslocation, GeneticUrinary Bladder NeoplasmsUrologic Neoplasms +[19] 
Inactive IndicationsSolid tumoursMyeloproliferative DisordersColitis, Ulcerative +[10] 

Other Information

ATC CodeL01XE
Related LinksDrugBankKEGG